<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464488</url>
  </required_header>
  <id_info>
    <org_study_id>cfx-adage-2015</org_study_id>
    <nct_id>NCT02464488</nct_id>
  </id_info>
  <brief_title>New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study</brief_title>
  <acronym>ADAGE</acronym>
  <official_title>Study of Interindividual Variability in the Response to New Oral Direct Anticoagulants (Dabigatran Etexilate, Rivaroxaban or Apixaban) in Patients 80 Years Old and Over, Using a Population Pharmacokinetics Approach.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Charles Foix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorbonne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital Charles Foix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several new oral direct anticoagulants have been recently marketed. However, only a few,&#xD;
      limited, studies have provided data about the pharmacology of new oral direct anticoagulants&#xD;
      in older persons. This study try to better define wether the pharmacology of each of these 3&#xD;
      drugs (dabigatran, rivaroxaban and apixaban) is actually significantly different in very&#xD;
      older patients (over 80) and to which extend. The investigators also try to characterize the&#xD;
      main determinants (age, weight, renal function, co-morbidities, etc) of the variability&#xD;
      observed between individuals in their response to he drugs studied. The method employed is a&#xD;
      population pharmacokinetic/pharmacodynamic study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several new oral direct anticoagulants have been recently marketed. A main indication for&#xD;
      taking these drugs is atrial fibrillation and, in everyday practice, most patients with&#xD;
      atrial fibrillation are older people. However, only a few, limited, studies have provided&#xD;
      data about the pharmacology of new oral direct anticoagulants in older persons. Furthermore,&#xD;
      this limited data strongly suggests that, in older patients, mean concentrations, overall&#xD;
      exposition and half-live of these drugs are increased, as compared with younger people. This&#xD;
      study try to better define wether the pharmacology of each of these 3 drugs (dabigatran,&#xD;
      rivaroxaban and apixaban) is actually significantly different in very older patients (over&#xD;
      80) and to which extend. The investigators also try to characterize the main determinants&#xD;
      (age, weight, renal function, co-morbidities, etc) of the variability observed between&#xD;
      individuals in their response to he drugs studied. The method employed is a population&#xD;
      pharmacokinetic/pharmacodynamic study. This is, many people (projected 225 patients) will&#xD;
      have a few blood samples each and all data will be pooled using statistical methods specific&#xD;
      to this kind of studies. Each patient will have one to five blood samples, taken at te same&#xD;
      time that routine blood analysis, to determine plasma concentrations of the studied drug. In&#xD;
      addition, patients will be followed for thrombotic and haemorrhagic events at 6 and 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">August 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacologic parameters of new oral anticoagulants in elderly patients</measure>
    <time_frame>1 to 3 weeks</time_frame>
    <description>Estimated area under the curve (AUC) of each of the 3 drugs studied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>1 year</time_frame>
    <description>Any thromboembolic event (composite of ischemic stroke, systemic embolism or acute coronary syndrome) in the year after inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic events</measure>
    <time_frame>1 year</time_frame>
    <description>Major hemorrhagic events in the year after inclusion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">232</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Main cohort (only cohort of the study)</arm_group_label>
    <description>Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma drug concentrations</intervention_name>
    <description>Measure of plasma concentrations of the anticoagulant drug taken by the patient</description>
    <arm_group_label>Main cohort (only cohort of the study)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban&#xD;
        because atrial fibrillation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 80 years or older&#xD;
&#xD;
          -  Under treatment with dabigatran, rivaroxaban or apixaban&#xD;
&#xD;
          -  For non-valvular atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mechanical (non-biological) heart valve&#xD;
&#xD;
          -  Any severe condition leading to a short estimated life expectance (a few months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmelo Lafuente, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Charles Foix, APHP, Université Paris 6 UPMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Le Guen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou, APHP, Université Paris 5 Descartes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Charles Foix</name>
      <address>
        <city>Ivry-sur-Seine</city>
        <state>Île-de-France</state>
        <zip>94205</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulants</keyword>
  <keyword>Factor Xa Inhibitors</keyword>
  <keyword>Antithrombins</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Aged, 80 years and older</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

